Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › UBT251

UBT251

GIP/GLP-1/GCG · s.c. · United Laboratories (Novo Nordisk licence)

Data cut 12 November 2026 · page built 16 November 2026 · 8 trial arms · 4 trials with results · 6 registered trials · see on the pipeline board

Summary

Also known as
United Laboratories
Mechanism
GIP/GLP-1/GCG
Route
s.c.
Company
United Laboratories (Novo Nordisk licence)
Highest development stage
phase 3
Status (as of data cut)
Phase 3 in China: UNIGUIDE-1 (T2D) recruiting since Sep 2026; obesity and sleep apnoea trials registered; phase 2 (T2D) at EASD 2026 verify
Next milestone
Phase 3 results in China (primary completion from Sep 2027)

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity2 phase 3 ongoingPhase 2 positive (EASD 2026: up to −19.7 % at 24 weeks); phase 3 ongoingUBT251 phase 2 obesity (EASD 2026)
T2D2 phase 3 ongoingPhase 2 positive (Cell Metabolism, October 2026); phase 3 ongoingUBT251 phase 2 T2D (EASD 2026); UBT251 phase 2 T2D, Cell Metab 2026
CV outcomes0 no data
CKD1 phase 2 / signalPhase 2 only
HFpEF0 no data
MASH1 phase 2 / signalPhase 2 only
Sleep apnoea2 phase 3 ongoingPhase 3 registered on ClinicalTrials.gov
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
UBT251 phase 2 (T2D)UBT251 2.0 mgt2d china24———−2.2 vs −0.7——————verified
UBT251 phase 2 (T2D)UBT251 6.0 mgt2d china24———−2.1 vs −0.7——————verified
UBT251 phase 2 (obesity)UBT251 4.0 mg (start 1.0 mg)obesity china24———−19.7 % vs −2.0 %
estimand not specified
———————verified
UBT251 phase 2 (obesity)UBT251 6.0 mgobesity china24———−18.7 % vs −2.0 %
estimand not specified
———————verified
UBT251 phase 2 (obesity)UBT251 2.0 mgobesity china24———−13.6 % vs −2.0 %
estimand not specified
———————verified
UBT251 phase 2 T2D China (NCT07163624)4.0 mg (initial dose 0.5 mg) vs semaglutide 1 mg: weight -4.8 %, HbA1c -1.77t2d china24211——−2.0 vs −0.7——————congress
UBT251 phase 2 T2D China (NCT07163624)4.0 mg (initial dose 1.0 mg) vs semaglutide 1 mg: weight -4.8 %, HbA1c -1.77t2d china24211——−2.1 vs −0.7——————congress
UBT251 phase 2 obesity China (NCT07177469)4.0 mg (initial dose 0.5 mg)obesity china24205——−16.2 % vs −2.0 %
estimand not specified
———————congress

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (8)
  • UBT251 4.0 mg (start 1.0 mg) · weight_unsp · Results
    LSM percentage change in weight
  • UBT251 6.0 mg · weight_unsp · Results
    LSM percentage change in weight
  • UBT251 2.0 mg · weight_unsp · Results
    LSM percentage change in weight
  • UBT251 2.0 mg · hba1c · Results
    LSM change in HbA1c
  • UBT251 6.0 mg · hba1c · Results
    LSM change in HbA1c
  • 4.0 mg (initial dose 0.5 mg) · weight_unsp · abstract
    change (95% CI) in weight being -13.6% (-15.3 to -11.8) in the 2.0 mg group, -16.2% (-18.7 to -13.6) in the 4.0 mg (ID, 0.5 mg)
  • 4.0 mg (initial dose 0.5 mg) · hba1c · abstract
    change in HbA1c was -2.16% (0.122), -1.98% (0.169), -2.08% (0.170) and -2.08% (0.118) with
  • 4.0 mg (initial dose 1.0 mg) · hba1c · abstract
    change in HbA1c was -2.16% (0.122), -1.98% (0.169), -2.08% (0.170) and -2.08% (0.118) with

Registered trials (6)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
UNISHAPE-OSA-1
UBT251 Injection Phase Ⅲ Study (OSA-NPAP)
Sleep apnoeaPhase 3not yet recruiting2026-12 → 2028-09150not yet recruitingNCT07767942
UNISHAPE-OSA-2
UBT251 Injection Phase Ⅲ Study (OSA-PAP)
Sleep apnoeaPhase 3not yet recruiting2026-10 → 2029-03150not yet recruitingNCT07806851
Overweight or Obesity
UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)
ObesityPhase 3active not recruiting2026-09 → 2027-09600active not recruitingNCT07648225
UNIGUIDE-1
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone(UNIGUIDE-1)
T2DPhase 3recruiting2026-09 → 2027-09360recruitingNCT07659574
NCT07134335
UBT251 Injection Phase II Clinical Study (CKD)
CKDPhase 2recruiting2025-09 → 2030-07180recruitingNCT07134335
NCT07145151
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
MASHPhase 2recruiting2025-09 → 2027-06156recruitingNCT07145151

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: UBT251. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/ubt251/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.